These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18565881)

  • 1. ERCC5 is a novel biomarker of ovarian cancer prognosis.
    Walsh CS; Ogawa S; Karahashi H; Scoles DR; Pavelka JC; Tran H; Miller CW; Kawamata N; Ginther C; Dering J; Sanada M; Nannya Y; Slamon DJ; Koeffler HP; Karlan BY
    J Clin Oncol; 2008 Jun; 26(18):2952-8. PubMed ID: 18565881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
    Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
    Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
    Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
    Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
    Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
    Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
    He C; Duan Z; Li P; Xu Q; Yuan Y
    Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J; D'Andrea AD; Kozono D
    J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.
    Liu D; Wu J; Shi GY; Zhou HF; Yu Y
    Genet Mol Res; 2014 Apr; 13(2):3100-7. PubMed ID: 24782167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.
    Yang N; Kaur S; Volinia S; Greshock J; Lassus H; Hasegawa K; Liang S; Leminen A; Deng S; Smith L; Johnstone CN; Chen XM; Liu CG; Huang Q; Katsaros D; Calin GA; Weber BL; Bützow R; Croce CM; Coukos G; Zhang L
    Cancer Res; 2008 Dec; 68(24):10307-14. PubMed ID: 19074899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
    Italiano A; Laurand A; Laroche A; Casali P; Sanfilippo R; Le Cesne A; Judson I; Blay JY; Ray-Coquard I; Bui B; Coindre JM; Nieto A; Tercero JC; Jimeno J; Robert J; Pourquier P
    Cancer; 2011 Aug; 117(15):3445-56. PubMed ID: 21287534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
    Zamagni C; Wirtz RM; De Iaco P; Rosati M; Veltrup E; Rosati F; Capizzi E; Cacciari N; Alboni C; Bernardi A; Massari F; Quercia S; D'Errico Grigioni A; Dietel M; Sehouli J; Denkert C; Martoni AA
    Endocr Relat Cancer; 2009 Dec; 16(4):1241-9. PubMed ID: 19749010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Luo S; Zhang Y; Yang Y; Zhu S; Liu W; Zhu J; Liang X; Jiang Z; Sun S; Hou X; Xiao Y; Li X
    Gynecol Oncol; 2020 Jul; 158(1):66-76. PubMed ID: 32402633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
    Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.